GlyCardial Diagnostics is a spin-off company of the Catalan Institute of Cardiovascular Sciences (ICCC) and the Spanish National Research Council (CSIC) focused on the development of a novel in vitro diagnostic device for myocardial ischemia. The technology is based on the detection of Apo J-Glyc in blood as a biomarker for the early diagnosis of cardiac ischemia and the prediction of patient’s evolution after an ischemic event. GlyCardial Diagnostics was created by scientists Lina Badimon, Judit Cubedo, Teresa Padró and Gemma Vilahur. The company is located at the Hospital de la Santa Creu i Sant Pau Art Nouveau Site in Barcelona. In 2014, it was recognised as one of the most original, impactful technology projects in Spain in the MIT Technology Review awards for innovators under 35.
Location: Spain, Catalonia, Barcelona
Employees: 11-50
Total raised: $5M
Founded date: 2017
Investors 2
| Date | Name | Website |
| 25.03.2022 | Healthequi... | healthequi... |
| 05.08.2021 | Caixa Capi... | caixacapit... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 07.01.2019 | Grant | $2.2M | - |
| 13.11.2017 | - | $2.8M | - |
Mentions in press and media 1
| Date | Title | Description |
| 13.11.2017 | GlyCardial Diagnostics Raises €2.4M in Funding | GlyCardial Diagnostics, a Barcelona, Spain-based biotechnology company, raised €2.4M in funding. The round was led by Caixa Capital Risc, with participation from HealthEquity. The company intends to use the funds to advance development of i... |